Mirum Pharmaceuticals director sells $1.33M in shares

Available on EDGAR 11/12/2026 - 08:34 AM EST Accepted by SEC EDGAR 11/12/2026 - 08:34 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Mirum Pharmaceuticals, Inc. (MIRM) director Laura Ann Brege reported a sale of 14,167 common shares on November 11, 2026. The notice lists an aggregate market value of $1,334,673.07. It also reports that Brege acquired 14,167 shares from the issuer through a stock option exercise paid in cash on November 11, 2026; the notice says the sales were executed that day.

Key Figures

Shares reported sold: 14,167 common shares Aggregate Market Value: $1,334,673.07 Issuer shares outstanding: 65,282,044 shares

3 metrics

Shares reported sold 14,167 common shares Sale executed November 11, 2026

Aggregate Market Value $1,334,673.07 For the shares reported sold

Issuer shares outstanding 65,282,044 shares Number stated in the securities information

Key Terms

Aggregate Market Value, Stock Option Exercise, Number of Shares or Other Units Outstanding

3 terms

Aggregate Market Value financial

"Aggregate Market Value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Stock Option Exercise financial

"Nature of Acquisition Transaction: Stock Option Exercise"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

Number of Shares or Other Units Outstanding financial

"Number of Shares or Other Units Outstanding"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MIRM shares did director Laura Ann Brege sell?

Laura Ann Brege reported a sale of 14,167 common shares on November 11, 2026. The notice lists an aggregate market value of $1,334,673.07 for the shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001365619
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	MIRUM PHARMACEUTICALS, INC.
SEC File Number	001-38981
Address of Issuer	989 East Hillsdale Boulevard, Suite 300 Foster City CALIFORNIA 94404
Phone	(650) 667-4085
Name of Person for Whose Account the Securities are To Be Sold	LAURA BREGE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	14167	1334673.07	65282044	11/11/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/11/2026	Stock Option Exercise	Issuer			14167	11/11/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	Sales that were executed on November 11, 2026 are being reported on this Form 144 filed on November 12, 2026 given the EDGAR system was not accepting filings on November 11, 2026 in observance of the federal holiday.
Date of Notice	11/12/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Laura Ann Brege
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)